Workenhe ST - Search Results

1

Level of expression of MHCI-presented neoepitopes influences tumor rejection by neoantigen-specific CD8+ T cells.

Deng L, Walsh SR, Nguyen A, Inkol JM, Westerveld MJ, Chen L, El-Sayes N, Mossman KL, Workenhe ST, Wan Y. Deng L, et al. Among authors: workenhe st. Cancer Immunol Res. 2024 Oct 8. doi: 10.1158/2326-6066.CIR-23-0639. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39377761

2

Determinants for Antitumor and Protumor Effects of Programmed Cell Death.

Workenhe ST, Inkol JM, Westerveld MJ, Verburg SG, Worfolk SM, Walsh SR, Kallio KLF. Workenhe ST, et al. Cancer Immunol Res. 2024 Jan 3;12(1):7-16. doi: 10.1158/2326-6066.CIR-23-0321. Cancer Immunol Res. 2024. PMID: 37902605 Free PMC article.

3

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Workenhe ST, et al. Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19. Cancer Immunol Res. 2013. PMID: 24777969

4

Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells.

Inkol JM, Westerveld MJ, Verburg SG, Walsh SR, Morrison J, Mossman KL, Worfolk SM, Kallio KL, Phippen NJ, Burchett R, Wan Y, Bramson J, Workenhe ST. Inkol JM, et al. Among authors: workenhe st. J Immunother Cancer. 2024 Apr 4;12(4):e006781. doi: 10.1136/jitc-2023-006781. J Immunother Cancer. 2024. PMID: 38580330 Free PMC article.

5

Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype.

Cuddington BP, Dyer AL, Workenhe ST, Mossman KL. Cuddington BP, et al. Among authors: workenhe st. Cancer Gene Ther. 2013 May;20(5):282-9. doi: 10.1038/cgt.2013.18. Epub 2013 Apr 26. Cancer Gene Ther. 2013. PMID: 23618948

6

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Workenhe ST, Mossman KL. Workenhe ST, et al. Mol Ther. 2014 Feb;22(2):251-256. doi: 10.1038/mt.2013.220. Epub 2013 Oct 19. Mol Ther. 2014. PMID: 24048442 Free PMC article. Review.

7

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.

Workenhe ST, Mossman KL. Workenhe ST, et al. Oncoimmunology. 2013 Dec 1;2(12):e27138. doi: 10.4161/onci.27138. Epub 2013 Dec 9. Oncoimmunology. 2013. PMID: 24498567 Free PMC article.

8

The role of oncolytic virus immunotherapies to subvert cancer immune evasion.

Workenhe ST, Verschoor ML, Mossman KL. Workenhe ST, et al. Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254. Future Oncol. 2015. PMID: 25686121 Review.

9

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.

van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW. van Vloten JP, et al. Among authors: workenhe st. J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021. J Immunol. 2018. PMID: 29311387 Review.

10

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, Pol J, Bramson JL, Wan Y. Nguyen A, et al. Among authors: workenhe st. Cell Rep. 2018 Jul 17;24(3):642-654. doi: 10.1016/j.celrep.2018.06.040. Cell Rep. 2018. PMID: 30021162 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters